The Lancet1d
The gut–bone axis: implications of gut hormone-based therapies for bone health
Historical trends and future projections of the number of people with overweight and obesity suggest alarming parallel ...
Medscape5d
Oral GLP-1 Receptor Agonist Reduces CV Risk
Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
Yahoo Finance6d
In the obesity triple-agonist blockbuster race, a familiar battle looms: Novo vs. Lilly
The candidate, which is still in early stages, targets the GLP-1, GIP and glucagon receptors. Novo’s blockbuster obesity and diabetes medications, Wegovy and Ozempic are GLP-1 receptor agonists, ...
The American Journal of Managed Care6d
SOUL Findings Highlight Cardiovascular Benefits Beyond Glycemic Control With Oral GLP-1
Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of ...
verywellhealth4d
How Hypoglycemia (Low Blood Sugar) Is Treated
For moderate to severe hypoglycemia due to diabetes, a prescription medication containing the hormone glucagon can be delivered by injection or nasal inhalation. Hypoglycemic emergencies, in which ...
The Scientist6d
The Scientist - Home
Current biomarkers of cognitive impairment in individuals with Alzheimer’s disease perform poorly. Now, a stronger predictor emerges.
C&EN5d
Discovery of New Difluorocyclobutyl Derivatives as Effective Glucagon-Like Peptide-1 Receptor Agonists with Reduced hERG Inhibitory Activities
Institute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China ...